Kingdom of Saudi Arabia

Ministry of Health

IPP
TITLE POLICY NUMBER APPLIES TO APPROVAL DATE REVISION DUE

INSTITUTIONAL POLICY AND PROCEDURE DRUG INTERACTION REPORTING PH-IPP-MOH-002E(1) All ICU Clinical Pharmacists 01.08.1432 01.08.1434 EFFECTIVE DATE NO. OF PAGES 01.09.1432 2 REPLACES NUMBER New

1.0 PURPOSE 1.1 Implementing strategy to prevent errors or adverse medical event induced by drug interaction. 1.2 Reviewing occurrence of drug interactions and develop corrective actions. 2.0 DEFINITION 2.1 Drug-Drug Interaction (DDI)
Can be defined as any unforeseen or undesirable clinical response occurring when two or more drugs are used concomitantly. This may subsequently cause a change in the pharmacodynamic or pharmacokinetic parameters which may lead to lack of efficacy or increased efficacy, or to an increase or a decrease in the number of reported Adverse Drug Reactions (ADRs). 2.2 Drug-Food Interactions (DFI) Can be defined as an unforeseen or undesirable clinical response occurred when a drug is administered with food or a particular type of food (e.g. calcium containing products interfere with the absorption of tetracycline and many other drugs).

3.0 RESPONSIBILITY This is the responsibility of the Head of the Clinical Pharmacy Services, clinical pharmacists, and all ICU Healthcare professionals. 4.0 EQUIPMENTS/ MATERIAL 4.1 Black Ink 4.2 Clinical pharmacist intervention Form 4.3 Medication Error Form 4.4 Occurrence Variance Accident report (OVAR) 4.5 Adverse Drug Reaction Form 5.0 POLICY
Medications can interact with both other drugs and food substances to produce undesirable clinical responses. Many drug interactions have been previously reported in the medical literature and it is the responsibility of the pharmacist to keep abreast of available literature concerning drug interactions and to use this knowledge to identify and prevent dangerous drug interactions where possible. In addition, as new drugs continue to become available, and new combinations of drugs and foods are employed, it is important to keep in mind that previously unreported drug interactions continue to surface.
File Name Page No. DRUG INTERACTION REPORTING PAGE 1 OF 1 File No. File location PH-IPP-MOH-002E(1) KSA MOH IPP Manual

Kingdom of Saudi Arabia

Ministry of Health

6.0 PROCEDURE 6.1 Drug interactions that result in adverse clinical outcomes shall be reported, evaluated and monitored as part of the Adverse Drug Reaction Reporting Program. 6.2 In addition, potential drug interactions (i.e. those that might result in serious patient complications or adverse clinical outcomes, if not recognized) that are identified by a pharmacist shall be documented including Occurrence Variance Accident report (OVAR) confidentially within 24 hours and send it to Quality Management Department through the quality assurance from the pharmacy. 6.3 The Clinical Pharmacist shall directly contact the doctor regarding any matters involving the prescribers immediate attention. 6.4 Any clinician discovering an actual or suspected drug interaction involving one or more medications and/or foods shall notify the prescribing or attending doctor and complete the Adverse Drug Reaction (ADR) Reporting form. 6.5 The completed form shall be forwarded to the ICU Clinical Pharmacy Services. 6.6 The Critical Care Clinical Pharmacist coordinator shall review information provided in the report, and take appropriate follow-up action. 6.7 The Head of Critical Care Clinical Pharmacy Services will send report periodically to the pharmacy director and head of ICU. 6.8 Any trends within the ICU shall be noted and communicated to other staff as appropriate. 7.0 REFERENCES
Prince Sultan Cardiac Center, Department of Pharmacy Services Policies and Procedures Drug Interaction Reporting Program Policy no. 03:35

8.0 APPROVAL: Name Prepared By Dr. Title Consultant Signature Date

Reviewed By

Approved By

File Name Page No.

DRUG INTERACTION REPORTING PAGE 2 OF 2

File No. File location

PH-IPP-MOH-002E(1) KSA MOH IPP Manual